INTRODUCTION
There is a large variety of bacterial genera, species, and strains in the human intestine; these bacteria are either beneficial (e.g., Bifidobacterium and Lactobacillus) or harmful (e.g., Clostridium, Salmonella and Staphylococcus) to the host's health. Bifidobacteria are a major bacterial group in the normal intestinal microflora (4) and may play an important role in the ecophysiology of the microflora (7) . As the effects of these bacteria have been revealed, there is currently much interest in the studies of prebiotics that stimulate the growth of beneficial bacteria in the intestine. A prebiotic is defined as "a nondigestible food ingredient that beneficially affects the host by selectively stimulating the growth and/or activity of one or a limited number of bacteria in the colon" (6) . In general, the prebiotics developed to date are nondigestible oligosaccharides.
Kaneko et al. (9) found a novel bifidogenic growth stimulator (BGS) produced by Propionibacterium freudenreichii, which is used extensively in the dairy industry as a starter culture for the manufacture of Swiss-type cheese. The BGS has a specific effect on the bifidobacterial growth at an extremely low concentration (9) . The BGS was produced both in cell free supernatant and in the nonpolar solvent extraction of the cell (9, 13) . In regard to prebiotic effects, it was reported that the bifidobacterial count and its ratio to total bacteria were increased when sterilized P.
freudenreichii culture was added to anaerobic continuous culture system simulating the bacterial ecosystem of human intestine (8, 10) . In in vitro models, moreover, harmful bacteria such as Clostridium perfringens and enterobacteriaceae were greatly decreased by the addition of sterilized P. freudenreichii culture (10) . However, to understand the potential value of the BGS and to progress in the development of the new prebiotics, an in vivo study is required.
The objective of the present study is to conclude whether the BGS acts as a useful bifidogenic factor in the human intestine. We studied the efficacy of the tablet containing P. freudenreichii culture on the bacterial composition of feces, fecal putrefactive products, and stool frequency and quantity in this double-blind, placebo-controlled crossover study.
MATERIALS AND METHODS
Bacteria. P. freudenreichii ET-3 used in this study was isolated from a Swiss-type cheese, and Bifidobacterium longum 6001 used as test microorganism for BGS activity assay is stocked in the Food Functionality Research Institute of Meiji Dairies Co., Odawara, Japan. Sample preparation. The test materials were administered in tablet form. The composition of the tablets is shown in Table 1 . P. freudenreichii ET-3 was grown at 35°C for 72 hr in 10% (wt/wt) milk whey medium, which was digested by Protease Amano A (Amano Pharmaceutical Co., Tokyo, Japan). During cultivation, the pH of the medium was adjusted to 6.0, using 8 N K2CO3 as a neutralizer. The culture was lyophilized and used for preparation of the foodstuff. Each subject was given 3 tablets (1.5 g) per day orally, which contained 24.8 U of BGS activity. Three tablets contained 0.03 g of protein, 0.04 g of lipid, 1.3 g of carbohydrate, and 3.0 mg of sodium. Placebo tablets were prepared with lyophilized whey medium instead of P. freudenreichii ET-3 culture. Study design. In this double-blind, placebo-controlled crossover study, the experimental period cornprised four two-week periods. The first of the experimental period was the control period. During the following 14 days, all subjects were administrated test tablets (3 per day) containing P. freudenreichii culture or a placebo after a meal, and neither the content of the tablets nor the group assignments were known to any of the subjects. The other test tablets were ingested after an interval of a 14-day nonintake period. The subjects followed their normal diet, but they were asked to consume no products containing probiotics or prebiotics and to limit the intake of alcoholic drinks. During the experimental period, the subjects provided the records of stool frequencies and quantities and general health conditions every day, as described below. Stool samples for the bacteriological and chemical analyses were collected on a random day between days 12 and 14 of each experimental period.
Bacteriologic analysis. An enumeration of bacterial populations in the feces was carried out under methods developed by Mitsuoka (11) . The samples obtained from each subject were introduced into an anaerobic chamber (N2, H2, CO2: 80%, 10%, 10% atmosphere). Then 1 g of the sample was suspended in 9 ml of trypticase soy broth without dextrose (BBL), supplemented with 0.084% (w/v) Na2CO3, 0.05% (w/v) agar, and 0.05% (w/v) L-cysteine hydrochloride. Serial tenfold dilutions from 10-1 to 10_8 were prepared of the same medium. Aliquots (0.1 ml) of each dilution were plated onto nonselective media or various selective media. After incubation, fecal bacteria were identified by colony and cell morphology, Gram-reactions, aerobic and anaerobic growth, and biochemical tests. The number of total bacteria and each genus was expressed in terms of colony forming unit per gram of feces. increase to 240°C, from 60°C, at 5°C per min, and the temperature of the injection port and flame ionization detector was 210°C. Assessment of questionnaire. The items of the quantity of stools were converted to numerical data as follows. The stool quantity was estimated by participants as the number of cakes of soap it was equivalent to. They also recorded their intake of any supplements for constipation, such as fermented milk or dietary fiber, and the intake of medicine, such as antibiotics or other drugs. All data were collected and reviewed by the investigators responsible for this study. 
RESULTS

Composition of Intestinal Microffora
Several groups of intestinal bacteria were enumerated to determine the microbial composition of feces ( Table 2 ). The bifidobacteria/total bacteria ratio during the BGS tablet intake period was significantly increased (p < 0.05) in comparison with those during the placebo tablet intake and control period. The number of bacteroidaceae in feces of the BGS tablet intake period was Table 2 . Mean bacterial counts (log10/g of feces) in fecal samples of 7 volunteers.
Mean values in the same row that are significantly different at p < 0.05 are indicated with different letter superscripts. *Frequency of occurrence . + Bifidobacteria population (%) to total fecal bacteria. lower (p = 0.091) than those of the placebo intake period, though there were no significant changes in other bacterial groups.
Fecal pH, Water, and Metabolite Concentration
The results in Table 3 show the change of the putrefactive products produced by the degradation of aromatic amino acids by intestinal bacteria during the experimental period. Compared with other experimental periods, fecal indole concentration during the intake of BGS tablets was significantly lowest (p < 0.05). During the BGS tablet intake period, fecal skatole concentration also decreased (p < 0.01, p = 0.063) in comparison with those of the placebo tablet intake and nonintake periods. There were no significant differences in fecal pH or water content. Table  4 . The stool frequency of the subjects in the lower frequency class (•… 4 times/ week) during BGS tablet intake was significantly higher (p < 0.05) than for those with control and placebo tablet intake. The change in stool quantity in the lower frequency class seemed to be consistent with the change in stool frequency. The stool quantity of the BGS tablet intake period was greater than that of the control period (p=0.088) and nonintake period (p = 0.061). For subjects of the normal class (> 4 times/week), there was no significant difference in stool frequency during the experimental period. The stool quantity of the BGS tablet intake period for all subjects was slightly higher (p = 0.083) than that of the nonintake period, and during placebo tablet intake period it significantly increased (p < 0.05) compared with that during the control period.
Questionnaire Result
DISCUSSION
It is believed that certain components in human breast milk such as high lactose, oligosaccharides, N-acetylglucosamine-containing saccharides, glycoproteins, and glucopeptides are growth factors for bifidobacteria (12, 16) . Indigestible carbohydrates, pantethine, lactulose, Kcasein, trypsin digest, and products of aminocarbonyl reaction also enhance the growth of bifidobacteria (2, 5, 15, 16) . Kaneko et al. (9) found that P. freudenreichii used traditionally as a Swiss-type cheese starter produced bifidogenic growth stimulator. In the culture of human feces, P. freudenreichii culture stimulated specifically the growth of bifidobacteria in the presence of several intestinal bacteria (8, 10) . This study, using human subjects, investigated whether the bacterial flora in the intestine and certain indexes of intestinal metabolism could be influenced by the consumption of BGS tablets made from P. freudenreichii culture.
The analysis of bacterial counts in feces revealed that bifidobacteria/ total bacteria ratio significantly increased after BGS tablet intake, but not after placebo tablet intake, and bacteroidaceae during a BGS tablet intake period was lower than that during a placebo intake period. By means of an anaerobic continuous culture system simulating the gut bacterial ecosystem, P.
freudenreichii culture also enhanced bifidobacterial percentage when a substrate was simultaneously added into that system, though bifidobacterial percentage decreased without P. freudenreichii culture (8) . It was suggested that the substrate was utilized by gut bacteria other than bifidobacteria, but that the P. freudenreichii culture with BGS most likely enhanced prior utilization of the substrate by bifidobacteria (8) . In this study, the growth stimulation of bifidobacteria may affect the decrease in bacteroidaceae during the BGS tablet intake period because bifidobacteria overwhelm their opponents in competition for the utilization of limited substrate in the intestine. According to the experiment design, the investigation of stool frequency and quantity by questionnaire was continued for 8 weeks, and none of the subjects mentioned problems such as abdominal pain and flatulence. Division of the subjects into two classes on the basis of stool frequency in the control period afforded interesting results upon comparison of the data for each experimental period. The stool frequency during the BGS tablet intake period for subjects in the lower-frequency class showed a significant increase as compared with those in the control period and the placebo tablet intake period. However, for subjects in the normal class, the inherent frequency was not affected by BGS tablet intake. These results indicate that the ingestion of BGS tablets increases the number of defecations of constipated volunteers to improve the balance of colonic bacteria toward a potentially healthier microflora. 
